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Abstract
Objectives. The aim of this pooled analysis of the TOZURA study programme was to evaluate the efficacy
and safety of subcutaneous tocilizumab (TCZ-SC) as monotherapy or in combination with conventional
synthetic DMARDs (csDMARDs) in patients with moderate to severe RA who had an inadequate response
to csDMARD or anti-TNF agent therapy or who were MTX naı¨ve.
Methods. TOZURA is a multinational, open-label, single-arm, common-framework, phase 4 study programme
(11 protocols, 22 countries). Patients received TCZ-SC 162 mg each week for524 weeks, administered at the
investigator’s discretion, as monotherapy or in combination with a csDMARD. Efficacy, safety and immuno-
genicity were evaluated; propensity scorebased matching was used for between-group comparisons.
Results. Of 1804 patients, 353 (19.6%) received monotherapy and 1451 (80.4%) received combination
therapy. The 28-joint DAS using ESR (DAS28-ESR) in both groups decreased significantly from baseline to
week 24 (mean change: monotherapy 3.40, combination therapy 3.46), with no significant difference
between groups (P= 0.46). The proportion of patients who achieved DAS28-ESR or Clinical Disease Activity
Index remission or ACR 20/50/70/90 responses was similar between groups. Overall, 13.9% of patients
withdrew—6.2% for safety reasons and 1.6% for insufficient therapeutic response; 5.8% of patients experi-
enced one or more serious adverse events [14.6/100 patient-years (PY)]; six deaths occurred (0.64/100 PY).
Conclusion. In a common framework of 11 studies in 22 countries, this phase 4 study programme con-
firmed TCZ-SC’s known efficacy and safety profile with comparable effects as monotherapy and in com-
bination with csDMARDs.
Trial registration: ClinicalTrials.gov (http://www.clinicaltrials.gov) NCT01941940, NCT01941095, NCT01951170,
NCT01987479, NCT01988012, NCT01995201, NCT02001987, NCT02011334, NCT02031471, NCT02046603
and NCT02046616.
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Rheumatology key messages
. Subcutaneous tocilizumab monotherapy and combination therapy with conventional synthetic DMARDs show com-
parable efficacy in patients with RA.
. The safety of subcutaneous tocilizumab monotherapy and combination therapy in RA is consistent with the
known tocilizumab profile.
. Subcutaneous tocilizumab’s low immunogenicity confirmed previous findings and has been established for mono-
therapy in RA.
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Introduction
Tocilizumab (TCZ), administered as intravenous (TCZ-IV)
or subcutaneous (TCZ-SC) formulations, is the first drug
approved worldwide for the treatment of RA that blocks
the biologic activity of IL-6. TCZ is a humanized mAb that
competitively interferes with the binding of IL-6 to its re-
ceptor (IL-6R; also known as IL-6Ra or CD126), thereby
disrupting receptor association with glycoprotein 130, a
co-signal transducer protein (also known as IL-6Rb or
CD130) necessary for initiating intracellular signalling [1].
The efficacy and safety of TCZ, both as monotherapy and
combination therapy with conventional synthetic DMARDs
(csDMARDs), have been demonstrated in numerous
clinical trials for patients with RA who had an inadequate
response to csDMARDs or anti-TNF agents [28].
Three phase 3 studies evaluated the efficacy and safety
of TCZ-SC as monotherapy or in combination with
csDMARDs. SUMMACTA (NCT01194414) demonstrated
the non-inferiority of TCZ-SC 162 mg administered once
a week (qw) to TCZ-IV 8 mg/kg administered every 4
weeks (q4w) in combination with csDMARDs with regard
to a 20% improvement in ACR criteria (ACR20) at
24 weeks [7]. BREVACTA (NCT1232569) demonstrated
that TCZ-SC 162 mg every 2 weeks in combination with
csDMARDs was superior to placebo in combination with
csDMARDs with regard to ACR20 at 24 weeks [8].
MUSASHI reported the non-inferiority of TCZ-SC 162 mg
every 2 weeks monotherapy compared with TCZ-IV 8 mg/
kg q4w monotherapy with regard to ACR20 at 24 weeks
[9]. All of the phase 3 studies had long-term extensions of
42 years that demonstrated the efficacy and safety of
TCZ-SC remained comparable to the known profile of
TCZ-IV [1013].
In addition to the rigorous phase 3 randomised clinical
trial setting, there is a need to understand the efficacy and
safety profile of TCZ-SC both as monotherapy and in
combination with csDMARDs in the less stringent phase
4 clinical setting. The objective of the TOZURA common-
framework study programme was to evaluate the efficacy,
safety and immunogenicity of TCZ-SC 162 mg qw as
monotherapy and in combination with csDMARDs over
24 weeks in adult patients with moderate to severe RA
in a broad geographic setting.
Methods
Patients
The study population included adult (518 years old) TCZ-
naı¨ve patients with active RA, per the revised 1987 ACR
criteria or 2010 EULAR/ACR criteria, who had an inade-
quate response to a csDMARD or an anti-TNF agent or
who were MTX naı¨ve. Active RA was defined by local
protocol; 10 of 11 protocols (the exception was Israel)
defined active RA of at least moderate severity as a 28-
joint DAS (DAS28) >3.2 at baseline. Some local protocols
also specified one or more of the following as inclusion
criteria: minimum CRP levels, minimum ESR, minimum
swollen and/or tender joint count and an inadequate
response to one or more biologic DMARD (bDMARD) (in
Israel, a minimum DAS28 score was not required for in-
clusion; however, 95 of 100 patients enrolled had DAS28
>3.2). Major exclusion criteria included ongoing rheumatic
or inflammatory joint diseases other than RA, functional
class IV status, previous treatment with TCZ, treatment
with any investigational agent, intra-articular or parenteral
glucocorticoids or immunization with a live/attenuated
vaccine 44 weeks before screening, treatment with alky-
lating agents or cell-depleting therapies, any active infec-
tions, history of malignancy, positive hepatitis B surface
antigen or hepatitis C antibody or serious allergies to bio-
logic agents. bDMARDs were prohibited and were discon-
tinued before initiation of the study.
The final protocols, amendments and informed consent
documentation of the studies were approved by the re-
spective local institutional review boards or independent
ethics committees of the investigational centres. All pa-
tients provided written, informed consent according to the
Declaration of Helsinki.
TOZURA phase 4 study programme design
TOZURA is a multinational, open-label, single-arm,
common-framework study programme comprising 7
single-country and 4 regional multicountry protocols (22
countries in total), ensuring similar study designs and data
collection for the core part of each individual study, which
comprises the first 24 weeks.
Patients received TCZ-SC 162 mg qw for 24 weeks, ad-
ministered at the investigator’s discretion as monotherapy
or in combination with a csDMARD. Concomitant
csDMARDs (AZA, chloroquine, HCQ, LEF, MTX or SSZ)
were permitted if patients maintained a stable dose for
54 weeks before baseline. Concomitant csDMARDs
could be used alone or in combination, except for the
combination of MTX and LEF. Stable oral NSAIDs and
glucocorticoids (410 mg/day prednisone or equivalent)
were permitted if initiated 54 weeks before baseline.
After the first treatment, TCZ-SC could be administered
at home by the patient or caregiver.
Efficacy and safety were evaluated at baseline and
weeks 1, 2 and 4 and every 4 weeks thereafter for 24
weeks, with 8 additional weeks for safety follow-up.
Clinical efficacy included total tender joint count, total
swollen joint count of 28 joints, Patient Global
Assessment of disease activity visual analogue scale
score, HAQ Disability Index (HAQ-DI), change in DAS28
using ESR (DAS28-ESR), ACR response scores, EULAR
response criteria, Clinical Disease Activity Index (CDAI),
Simplified Disease Activity Index and glucocorticoid
dose reduction and/or discontinuations. Safety assess-
ments included adverse events (AEs) with a focus on
AEs of special interest (AESIs), laboratory assessments,
physical examinations and vital signs. AESI categories
(serious or non-serious AEs) included serious and/or med-
ically significant infections, myocardial infarction/acute
coronary syndrome, gastrointestinal perforations, malig-
nancies, anaphylaxis/hypersensitivity reactions, demyeli-
nating disorders, stroke, serious and/or medically
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significant bleeding events and serious and/or medically
significant hepatic events. Immunogenicity assessments
were performed at baseline, weeks 12 and 24, study com-
pletion or early withdrawal visit and 8 weeks after the last
dose of TCZ-SC, as previously described [14].
Statistical methods
Descriptive statistical methods were used to evaluate ef-
ficacy and safety. The primary analysis population for ef-
ficacy and safety consisted of all patients who received
one or more dose of TCZ-SC. The proportion of patients
experiencing one or more safety event was estimated with
a 95% ClopperPearson CI. CIs for event incidence rates
by patient-years (PY) with TCZ exposure were analysed
based on the Poisson distribution. The KaplanMeier
method was used for time-to-event data. Propensity scor-
ebased 1:1 matching was used for selected between-
group comparisons, which employed the Wilcoxon
signed-rank test for continuous variables and the
McNemar test for categorical variables. For other be-
tween-group comparisons, the Wilcoxon rank-sum test
for continuous variables and the chi-square test for
categorical variables were used.
Results
Patient disposition and baseline characteristics
Of the 1804 patients enrolled, 353 patients (19.6%)
received TCZ-SC qw monotherapy and 1451 patients
(80.4%) received TCZ-SC qw with a concomitant
csDMARD (Fig. 1). During the 24-week period, 66 patients
(18.7%) discontinued from the TCZ-SC monotherapy
group and 185 patients (12.7%) from the combination
therapy group. The most common reason for withdrawal
during the 24-week study period was AEs. Of the patients
who completed 24 weeks, 287 patients (81.3%) were from
the monotherapy group and 1266 patients (87.3%) were
from the combination therapy group.
Patient baseline demographics and clinical characteristics
were balanced between the TCZ-SC monotherapy and the
TCZ-SC combination therapy groups, except for gluco-
corticoid use, which was less frequent in the TCZ-SC mono-
therapy group than in the combination group (41.1% vs
51.2%); however, the mean dose was similar between the
groups (6.6 vs 6.5 mg/day, respectively) (Table 1). A total of
348 patients (19.3%) had previously received a bDMARD,
with etanercept being the most common previous biologic
(overall 4.8%, monotherapy 7.1%, combination therapy
4.2%). Patients who received prior bDMARD treatment
made up a significantly greater proportion of the monother-
apy group than the combination therapy group (monother-
apy 31.4%, combination therapy 16.3%; P< 0.001).
Efficacy
The proportion of patients who achieved DAS28-ESR re-
mission (DAS28-ESR <2.6; TCZ-SC monotherapy 59.0%
vs TCZ-SC combination therapy 62.6%), low disease ac-
tivity (DAS28-ESR 2.643.2) or moderate disease activity
(DAS28-ESR >3.245.1) was similar between groups
over 24 weeks (Fig. 2). DAS28-ESR decreased compar-
ably from baseline to week 24 in both the monotherapy
and combination therapy groups [mean change: mono-
therapy 3.40 (S.D. 1.41), combination therapy 3.46
(S.D. 1.43); P< 0.0001 for both], with no significant differ-
ence between groups (P= 0.46) (Fig. 3A).
The proportion of patients who achieved CDAI remis-
sion (CDAI 42.8; monotherapy 26.3% vs combination
therapy 26.4%), low disease activity (CDAI >2.8410.0)
or moderate disease activity (CDAI >10.0422.0) was
similar between the monotherapy and combination ther-
apy groups (Fig. 2). The CDAI score decreased compar-
ably from baseline to week 24 in both groups [mean
change: monotherapy 23.54 (S.D. 13.52), combination
therapy 23.83 (S.D. 13.52); P< 0.0001 for both], with no
significant difference between groups (P= 0.57) (Fig. 3B).
In addition, EULAR and ACR20/50/70/90 response
rates were similar between treatment groups at week
24, with 73.3 and 77.5% of patients achieving a EULAR
good response and 57.2 and 57.7% achieving an ACR50
response in the monotherapy and combination therapy
FIG. 1 Patient disposition at baseline
csDMARD: conventional synthetic disease-modifying anti-rheumatic drug; qw: once weekly; TCZ-SC: subcutaneous
tocilizumab.
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groups, respectively (Fig. 4). Swollen joint counts and
tender joint counts over time were similar between the
monotherapy and combination therapy groups (supple-
mentary Fig. S1, available at Rheumatology Online).
The HAQ-DI score decreased comparably from base-
line to week 24 in both groups [mean change: monother-
apy 0.56 (S.D. 0.63), combination therapy 0.57 (S.D.
0.62); P< 0.0001 for both], with no significant difference
between groups (P= 0.72) (Fig. 3C).
Higher body weight was associated with reduced
efficacy of TCZ-SC. Compared with patients with high
weight (5100 kg), the mean decrease in DAS28-ESR
from baseline to week 24 was greater for patients with
intermediate weight (60<100 kg; difference, 0.22 DAS28
units) and for patients with low weight (<60 kg; difference,
0.31 DAS28 units). Compared with patients with high
weight, the odds ratio for ACR50 for patients with inter-
mediate weight and low weight were 1.37 and 1.84, re-
spectively. The P-value for the weight factor in respective
analysis of covariance and in logistic regression models
with adjustment for baseline DAS28-ESR and concomitant
csDMARDs was 0.085 and 0.021, respectively.
When propensity scorebased matched pairs of patients
were analysed from the monotherapy and combination ther-
apy groups, no statistical differences were observed for the
mean change from baseline in the DAS28-ESR and CDAI
score at week 24 (P= 0.86 and P= 0.66, respectively) and in
the proportion of patients achieving ACR20 and ACR50 at
week 24 (P= 0.71 and P= 0.51, respectively) (supplementary
Table S1, available at Rheumatology Online).
Treatment persistence with TCZ-SC through week 24,
measured as a binary proportion of patients who continued
therapy, was significantly higher in the combination therapy
group (supplementary Table S1, available at Rheumatology
Online). KaplanMeier estimates for the proportion of pa-
tients who received TCZ-SC through week 24 were 0.81
(95% CI 0.76, 0.84) for monotherapy and 0.87 (95% CI
0.85, 0.89) for combination therapy (supplementary Fig. S2,
available at Rheumatology Online). The difference between
treatment groups was statistically significant (P= 0.002, log-
rank test; P=0.029, propensity scorebased analysis).
Safety
The total TCZ exposure was 175.7 and 767.6 PY for the
monotherapy and combination therapy groups, respect-
ively (Table 2).
Overall, the AE rate per 100 PY was 622.4, with similar
rates between the monotherapy and combination therapy
groups (622.1 vs 622.5) (Table 2). The most common AEs
were infections and infestations, occurring in 42.0% of
patients (monotherapy 43.1%, combination therapy
41.8%), with nasopharyngitis occurring the most fre-
quently. Overall, 6.2% of patients discontinued the study
due to safety reasons (monotherapy 8.8%, combination
therapy 5.5%). The most common reasons for withdrawal
due to AEs were skin and subcutaneous disorders in the
monotherapy group [5 patients (1.4%)] and laboratory
findings [16 patients (1.1%)] in the combination therapy
group. There were 29 patients (1.6%) who withdrew due to
insufficient therapeutic response, slightly more in the mono-
therapy than in the combination therapy group (Table 2).
AESIs occurred at a rate of 16.1/100 PY in the total
population (monotherapy 15.4/100 PY, combination ther-
apy 16.3/100 PY). AESIs that occurred in >0.3% of the
total population included pneumonia, herpes zoster infec-
tion, transaminase increase, hypersensitivity and injection
site erythema. The rate of injection site reactions in the
total population was 31.7/100 PY.
TABLE 1 Baseline characteristics
Patient characteristics at baseline (week 1)
Total population
(N= 1804)
TCZ-SC monotherapy
(n= 353)
TCZ-SC + csDMARD
(n= 1451)
Female, n (%) 1472 (81.6) 295 (83.6) 1177 (81.1)
Age, mean (S.D.), years 54.1 (12.3) 55.0 (12.6) 53.9 (12.2)
Weight, mean (S.D.), kg 72.8 (16.3) 72.1 (16.9) 73.0 (16.1)
RA duration, mean (S.D.), years 7.7 (8.0) 8.4 (8.2) 7.6 (7.9)
Seropositivity, n (%)a 1367 (82.7) 262 (82.1) 1105 (82.8)
RF positive 1208 (72.6) 237 (72.5) 971 (72.7)
ACPA positive 1052 (70.8) 199 (69.3) 853 (71.1)
Evidence of structural joint damage, n (%) 723 (46.7) 172 (56.4) 551 (44.3)
CRP, mean (S.D.), mg/l 15.0 (21.8) 17.6 (24.7) 14.3 (20.9)
Disease activity
DAS28-ESR, mean (S.D.) 5.77 (1.17) 5.84 (1.12) 5.75 (1.18)
CDAI, mean (S.D.) 32.16 (12.81) 31.75 (12.26) 32.26 (12.94)
HAQ-DI, mean (S.D.) 1.38 (0.69) 1.45 (0.67) 1.36 (0.69)
Glucocorticoid use, n (%) 888 (49.2) 145 (41.1) 743 (51.2)
Prednisone equivalent daily dose, mean (S.D.), mg 6.5 (4.0)b 6.6 (2.9)c 6.5 (4.2)d
Previous bDMARD treatment, n (%) 348 (19.3) 111 (31.4) 237 (16.3)
aSeropositivity, total population positive for RF and/or ACPA. bn= 870. cn= 145. dn= 725. bDMARD: biologic disease-modifying
anti-rheumatic drug; CDAI: Clinical Disease Activity Index; csDMARD: conventional synthetic disease-modifying anti-rheumatic
drug; DAS28-ESR: Disease Activity Score in 28 joints using erythrocyte sedimentation rate; HAQ-DI: Health Assessment
Questionnaire-Disability Index; IR: inadequate response; RA: rheumatoid arthritis; TCZ-SC: subcutaneous tocilizumab.
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Overall, 105 patients (5.8%) reported one or more ser-
ious AE (SAE). SAEs were reported in 29 (8.2%) and 76
(5.2%) patients in the monotherapy and combination ther-
apy groups, respectively. The overall SAE rate was 14.6/
100 PY (monotherapy 22.8/100 PY, combination therapy
12.8/100 PY). The most common SAEs were infections
and infestations, with an overall rate of 3.6/100 PY and
similar rates between groups (monotherapy 4.0/100 PY,
combination therapy 3.5/100 PY). Three non-fatal gastro-
intestinal perforations occurred (overall 0.32/100 PY,
monotherapy 0.57/100 PY, combination therapy 0.26/
100 PY); one diverticular perforation in each group and
one duodenal perforation in the monotherapy group also
occurred. Three patients had myocardial infarctions clas-
sified as SAEs (overall 0.32/100 PY, monotherapy 0.57/
100 PY, combination therapy 0.26/100 PY), two in the
combination therapy group and one in the monotherapy
group, and one patient had a stroke classified as an SAE
in the combination therapy group. Overall, two patients
had serious anaphylactic reactions, both in the combin-
ation therapy group, and nine had serious hypersensitivity
reactions (defined as AEs occurring within 24 h of infusion/
injection and excluding injection site reactions), two in the
monotherapy group and seven in the combination therapy
group. One patient had a serious opportunistic infection of
disseminated tuberculosis (combination therapy group).
Six deaths occurred (0.64/100 PY), one due to coronary
artery disease in the monotherapy group (0.57/100 PY)
and five in the combination therapy group (0.65/100 PY)
due to myocardial infarction, pneumonia (bacterial), pul-
monary fibrosis, sepsis (bacterial) and septic shock
(fungal).
Of the patients with a normal neutrophil count at baseline
(n=1395) who developed a low neutrophil count after initiating
TCZ-SC,mostexperiencedNationalCancer InstituteCommon
Terminology Criteria grade 1 (overall 22.2%, monotherapy
23.2%, combination therapy 22.0%) or grade 2 (18.7%,
15.2% and 19.6%, respectively) neutropenia. No differences
were observed between groups for grade 3 or 4 neutropenia
[monotherapy 5.4% (grade 3 only), combination therapy 5.9%
(5.7% grade 3 and 0.2% grade 4)]. No serious infections
occurred following grade 4 neutropenia.
Of the patients with normal alanine aminotransferase (ALT)
values at baseline (n= 1361), 46.5% had elevated levels
upon initiation of TCZ-SC, with a higher proportion of pa-
tients having elevations in the combination therapy group.
Most shifts were43 the upper limit of normal (ULN; overall
41.7%, monotherapy 28.4%, combination therapy 44.9%).
Similar results were observed for aspartate aminotransferase
(AST) values (n= 1430), with 35.7% of patients having ele-
vated levels after initiating TCZ-SC; most patients had shifts
that were 43 ULN (overall 33.6%, monotherapy 20.8%,
combination therapy 36.6%). In the monotherapy group,
1.8% and 0.7% had ALT and AST shifts, respectively, from
normal at baseline to >35 ULN; no patients had shifts
from normal at baseline to >5 ULN. In the combination
therapy group, 3.7% and 1.5% had ALT and AST shifts,
respectively, from normal at baseline to >35 ULN; 1.7%
and 0.8% had ALT and AST shifts, respectively, from normal
at baseline to >5 ULN.
Among 1179 patients screened with the immunogenicity
assay, 14 (1.2%) developed treatment-induced anti-TCZ
antibodies (monotherapy 1.9%, combination therapy 1.0%)
(supplementary Table S2, available at Rheumatology Online).
FIG. 2 DAS28-ESR and CDAI disease activity at week 24
No imputation of data was used. CDAI: Clinical Disease Activity Index; csDMARD: conventional synthetic disease-
modifying anti-rheumatic drug; DAS28-ESR: Disease Activity Score in 28 joints using erythrocyte sedimentation rate;
TCZ-SC: subcutaneous tocilizumab.
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Of these, 13 patients (1.1%) tested positive for neutralizing
potential (monotherapy 1.9%, combination therapy 0.9%)
and none tested positive for IgE isotype. None of the patients
who developed anti-TCZ antibodies experienced anaphyl-
axis, serious hypersensitivity reactions or loss of efficacy.
Discussion
The TOZURA phase 4 study programme assessed the
efficacy, safety and immunogenicity of TCZ-SC qw mono-
therapy and TCZ-SC qw in combination with a csDMARD
in patients with RA who had an inadequate response to
csDMARDs or an anti-TNF agent or were MTX naı¨ve.
Patients demonstrated significant efficacy improvements
over 24 weeks in both groups, with improvements compar-
able between groups at 24 weeks. TCZ-SC was well toler-
ated and the safety profile was consistent with the known
profile of TCZ. No new safety signals were identified.
Overall, the efficacy data in this study show the benefit of
TCZ-SC as monotherapy or combination therapy since pa-
tients significantly improved from baseline to week 24 in
ACR and EULAR response rates, DAS28-ESR, CDAI and
HAQ-DI outcomes. Comparable efficacy responses be-
tween TCZ monotherapy and combination therapy have
FIG. 3 Mean (A) DAS28-ESR, (B) CDAI score and (C) HAQ-DI score over 24 weeks
*P < 0.0001 for TCZ-SC monotherapy comparing week 1 with week 24. **P < 0.0001 for TCZ-SC + csDMARD comparing
week 1 with week 24. BL: baseline; CDAI: Clinical Disease Activity Index; csDMARD: conventional synthetic disease-
modifying anti-rheumatic drug; DAS28-ESR: Disease Activity Score in 28 joints using erythrocyte sedimentation rate;
HAQ-DI: Health Assessment Questionnaire-Disability Index; TCZ-SC: subcutaneous tocilizumab.
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also been observed in clinical trials. The ACT-RAY and
FUNCTION clinical trials showed that patients with RA,
including early RA, who received TCZ-IV 8mg/kg monother-
apy achieved DAS28-ESR remission at week 24 at similar
rates compared with patients who received TCZ-IV 8mg/kg
with concomitant MTX (ACT-RAY 34.8% vs 40.4%,
FUNCTION 39% vs 45%) [15, 16]. The ACT-SURE open-
label clinical trial of patients with RA who had an inadequate
response to prior treatments found that similar proportions of
patients who received TCZ-IV as monotherapy and combin-
ation therapy achieved DAS28 remission at week 24 (61% vs
62%). Similar to the TOZURA study programme, the ACT-
SURE study featured a broad geographic range (25 countries)
with less stringent conditions than the phase 3 trials [17].
Treatment persistence with TCZ-SC was lower in the
monotherapy group compared with combination therapy.
This difference in persistence may be due to unobserved
differences in characteristics between the two groups.
Patients in the monotherapy group were more likely to
have received prior bDMARD treatment and less likely to
be receiving glucocorticoids at baseline compared with
the combination therapy group. However, the propensity
scorebased analysis indicated these confounders did not
fully explain the difference in persistence.
Safety outcomes at 24 weeks in all patients were con-
sistent with previous studies and were similar between the
monotherapy and combination therapy groups. The rate
of AEs in this study per 100 PY was consistent with the
rate observed in the ACT-SURE study, an open-label clin-
ical trial with a similar patient population (622.4 vs 593),
except for the known difference of more frequent injection
site reactions occurring with TCZ-SC compared with TCZ-
IV. The rate of SAEs for TCZ-SC qw monotherapy in this
study per 100 PY was similar to the rate observed for
TCZ-SC monotherapy in the 2-year long-term extension
of the MUSASHI study, which also studied TCZ-SC qw
monotherapy (22.8 vs 16.9) [12]. The rate of SAEs for com-
bination therapy in this study was also similar to the rates
in the 97-week long-term extension of the SUMMACTA trial
for TCZ-SC with concomitant csDMARDs (12.8 vs 14.61)
[10]. Serious infections were the most commonly reported
SAE in this study, occurring at rates similar to those re-
ported for TCZ-SC monotherapy in the MUSASHI long-
term extension (4.0 vs 5.3) and for combination therapy in
the SUMMACTA long-term extension (3.5 vs 3.95) [10, 12].
As also observed in other studies, elevated transaminase
levels were more commonly associated with concomitant
MTX than with TCZ monotherapy. The proportions of pa-
tients who received monotherapy or combination therapy in
this study who had shifts in ALT levels from normal to>35
ULN and to >5 ULN were similar to those observed in the
ACT-RAY study (monotherapy: >35 ULN 1.8% vs 0.8%
and >5 ULN 0.0% vs 0.4%; combination therapy: >35
ULN 3.7% vs 5.7% and >5 ULN 1.7% vs 2.0%); similar
trends were observed for shifts in AST levels [15].
Immunogenicity is a concern for mAb biologic therapies
because the development of anti-drug antibodies may
potentially affect the efficacy of the drug and lead to
hypersensitivity reactions [18]. In this study programme,
immunogenicity was infrequent in both the monotherapy
(not previously addressed in clinical trials) and the com-
bination therapy groups. This result is consistent with the
previously reported low immunogenicity for TCZ in pa-
tients with RA in clinical trial populations; including interim
immunogenicity data from this study [19].
This study programme has several limitations. It did not
have a control group; all patients received TCZ-SC.
Discontinuation and missing data rates were high and
were not balanced between the monotherapy and com-
bination therapy groups. In addition, we did not impute
FIG. 4 ACR and EULAR responses at week 24
No imputation of data was used. ACR: American College of Rheumatology; csDMARD: conventional synthetic disease-
modifying anti-rheumatic drug; EULAR: European League Against Rheumatism; TCZ-SC: subcutaneous tocilizumab.
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missing values into these analyses. Treatment choice
was at investigator discretion, therefore confounders
and confounding by indication may have affected the
comparison of monotherapy and combination therapy.
The propensity scoreadjusted results suggest that
these potential confounders would not change the overall
conclusions.
The TOZURA phase 4 study programme demonstrated
that TCZ-SC was efficacious in patients with RA, with
combination therapy and monotherapy being comparably
effective and with the observed safety profile being con-
sistent with the known TCZ profile.
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TABLE 2 Summary of adverse events
Events
Total population
(N= 1804), 943.3 PY
TCZ-SC monotherapy
(n= 353), 175.7 PY
TCZ-SC + csDMARD
(n= 1451), 767.6 PY
Adverse events
Patients with 51 AE, n (%) 1508 (83.6) 282 (79.9) 1226 (84.5)
Rate, per 100 PY 622.4 622.1 622.5
Serious adverse events
Patients with 51 SAE, n (%) 105 (5.8) 29 (8.2) 76 (5.2)
Rate, per 100 PY 14.6 22.8 12.8
Serious infections and infestations
Patients with 51 event, n (%) 27 (1.5) 6 (1.7) 21 (1.4)
Rate, per 100 PY 3.6 4.0 3.5
Serious GI perforations
Patients with 51 event, n (%) 3 (0.2) 1 (0.3) 2 (0.1)
Rate, per 100 PY 0.32 0.57 0.26
Serious anaphylactic reactions
Patients with 51 event, n (%) 2 (0.1) 0 2 (0.1)
Rate, per 100 PY 0.21  0.26
Serious hypersensitivity reactionsa
Patients with 51 event, n (%) 9 (0.1) 2 (0.6) 7 (0.5)
Rate, per 100 PY 1.3 2.8 0.91
Adverse events of special interestb
Patients with 51 AESI, n (%) 123 (6.8) 25 (7.1) 98 (6.8)
Rate, per 100 PY 16.1 15.4 16.3
Withdrawals
Patients, n (%) 251 (13.9) 66 (18.7) 185 (12.7)
Withdrawals due to safety reasonsc
Patients, n (%) 111 (6.2) 31 (8.8) 80 (5.5)
Withdrawals due to insufficient therapeutic response
Patients, n (%) 29 (1.6) 9 (2.5) 20 (1.4)
Deaths
Patients, n (%) 6 (0.3) 1 (0.3)d 5 (0.3)e
Rate, per 100 PY 0.64 0.57 0.65
aSAEs occurring during or within 24 h of the injection/infusion, excluding injection site reactions and not deemed to be
unrelated to treatment by the investigator. bAESI categories (serious or non-serious AEs) included serious and/or medically
significant infections, myocardial infarctions/acute coronary syndrome, GI perforations, malignancies, anaphylaxis/hypersen-
sitivity reactions, demyelinating disorders, stroke, serious and/or medically significant bleeding events and serious and/or
medically significant hepatic events. cDeaths not included. dCoronary artery disease. eMyocardial infarction, pneumonia, pul-
monary fibrosis, sepsis and septic shock. AE: adverse event; AESI: AE of special interest; csDMARD: conventional synthetic
disease-modifying anti-rheumatic drug; GI: gastrointestinal; SAE: serious adverse event; PY, patient-year; TCZ-SC: subcuta-
neous tocilizumab.
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